FDA Grants Orphan Drug and Rare Pediatric Disease Designations to Grünenthal’s Tegacorat for Duchenne Muscular Dystrophy Treatment

Aachen, 08 July 2026 – Grünenthal, a global leader in pain management and related diseases, announced today that their investigational compound tegacorat (GRM-01) has received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid Receptor Agonist…

Source

FDA Grants Orphan Drug and Rare Pediatric Disease Designations to Grünenthal’s Tegacorat for Duchenne Muscular Dystrophy Treatment

Next generation of Lionesses at risk as girls’ grassroots football goes chronically underfunded

UK tech funding nearly doubles to $15.3bn, but the money is going to fewer companies

UK tech funding nearly doubles to $15.3bn, but the money is going to fewer companies

Pibit.AI raises $7m Series A to bring trusted AI underwriting to the insurance sector

Gold Prices Rise as the Dollar Slowly Dies

Richard Murphy, The Bank of England, And MMT Confusion

We Can’t Fix International Organizations like the WTO. Abolish Them.

UK tech funding nearly doubles to $15.3bn, but the money is going to fewer companies

Ana-Maria Coaching Marks Milestone with New Book Release

New Bonded Warehouse Facilities Launched in Immingham

From Corporate Burnout to High-Performance Coach: Anna Mosley’s Inspiring Journey with ‘Eighty’

Robotic harvesting pioneer Dogtooth secures £14m to help growers beat labour shortages

UK tech funding nearly doubles to $15.3bn, but the money is going to fewer companies

FDA Grants Orphan Drug and Rare Pediatric Disease Designations to Grünenthal’s Tegacorat for Duchenne Muscular Dystrophy Treatment

Next generation of Lionesses at risk as girls’ grassroots football goes chronically underfunded

Recent News

Robotic harvesting pioneer Dogtooth secures £14m to help growers beat labour shortages

UK tech funding nearly doubles to $15.3bn, but the money is going to fewer companies

FDA Grants Orphan Drug and Rare Pediatric Disease Designations to Grünenthal’s Tegacorat for Duchenne Muscular Dystrophy Treatment

Next generation of Lionesses at risk as girls’ grassroots football goes chronically underfunded